Vercise DBS System

Boston Scientific has secured CE Mark for its Vercise Primary Cell (PC) Deep Brain Stimulation (DBS) system for the treatment of Parkinson’s disease (PD).

The Vercise PC system was designed to provide accurate neural targeting to address various requirements of patients suffering from PD, primary and secondary dystonia, and essential tremor.

Capable of finely controlling the size and shape of stimulation with multiple independent current control technology, the system also powers the Vercise DBS Directional Lead, the first commercially available eight-contact segmented lead with current steering.

"This new system exemplifies the Boston Scientific commitment to advancing DBS therapy and providing impactful and transformative technology."

The system comprises unique software solutions with a clinical effects map, which captures data over time and visually summarises the progress of individualised patient therapy, while allowing physicians to monitor and modify treatment as needed.

Boston Scientific neuromodulation president Maulik Nanavaty said: "This new system exemplifies the Boston Scientific commitment to advancing DBS therapy and providing impactful and transformative technology to reach a broader range of patients suffering from these debilitating diseases."

DBS therapy involves the placement of a device that stimulates specific areas in the brain using electrical signals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The portfolio is said to be supported by a robust clinical programme, including the ongoing Intrepid clinical trial in the US and the Vantage study in Europe, with the latter demonstrating a significant and consistent improvement in motor scores as well as an increase in quality of life.

While the Vercise PC DBS system is not available for use or sale in the US, its rechargeable version is investigational in the country, and is currently being evaluated in the Intrepid study.

Image: The Vercise Deep Brain Stimulation system is designed for the treatment of Parkinson’s disease. Photo: courtesy of Boston Scientific.